Anti-PD1 antibody: a new approach to treatment of lymphomas

Lancet Oncol. 2014 Jan;15(1):7-8. doi: 10.1016/S1470-2045(13)70587-4. Epub 2013 Dec 11.

Authors

Emmanuel Bachy¹, Bertrand Coiffier²

Affiliations

¹ Hematology Department, Hospices Civils de Lyon, Lyon, France; Hematology Department University Lyon 1, Lyon, France; Centre Hospitalier Lyon-Sud, 69310 Pierre-Bénite, France.
² Hematology Department, Hospices Civils de Lyon, Lyon, France; Hematology Department University Lyon 1, Lyon, France; Centre Hospitalier Lyon-Sud, 69310 Pierre-Bénite, France. Electronic address: bertrand.coiffier@univ-lyon1.fr.

PMID: 24332517
DOI: 10.1016/S1470-2045(13)70587-4

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Humans
Lymphoma, Follicular / drug therapy*
Male
Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Programmed Cell Death 1 Receptor
pidilizumab